member
coronaviru
famili
respons
current
pandem
previous
demonstr
four
nucleotid
analogu
specif
activ
triphosph
form
sofosbuvir
alovudin
azt
tenofovir
alafenamid
inhibit
rnadepend
rna
polymeras
rdrp
tenofovir
emtricitabin
two
compon
descovi
truvada
two
fdaapprov
medic
use
preexposur
prophylaxi
prep
prevent
hiv
infect
prevent
method
individu
hiv
neg
highrisk
contract
viru
take
combin
drug
daili
reduc
chanc
becom
infect
hiv
prep
stop
hiv
replic
spread
throughout
bodi
report
triphosph
tenofovir
emtricitabin
two
compon
descovi
truvada
act
termin
rdrp
catalyz
reaction
result
provid
molecular
basi
evalu
potenti
descovi
truvada
prep
pandem
caus
novel
coronaviru
reach
critic
level
worldwid
still
spread
member
subgenu
sarbecoviru
orthocoronavirina
subfamili
coronavirus
singlestrand
rna
virus
share
properti
rna
virus
hepat
c
viru
hcv
west
nile
viru
marburg
viru
hiv
ebola
viru
dengu
viru
rhinovirus
coronavirus
hcv
flavivirus
positivesens
singlestrand
rna
virus
share
similar
replic
mechan
requir
rnadepend
rna
polymeras
rdrp
catalyz
reaction
although
potenti
drug
candid
design
target
nearli
everi
stage
viral
infect
effect
drug
current
approv
treat
rdrp
coronavirus
precis
welldefin
drug
target
activ
site
rdrp
highli
conserv
among
differ
positivesens
rna
virus
share
common
structur
featur
virus
rdrp
includ
coronaviru
polymeras
low
fidel
enabl
recogn
varieti
modifi
nucleotid
analogu
substrat
nucleotid
nucleosid
analogu
may
inhibit
rnapolymeras
catalyz
rna
replic
therefor
import
candid
antivir
agent
previou
studi
use
molecular
analysi
design
select
nucleotid
analogu
potenti
inhibitor
rdrp
particular
focu
two
key
properti
similar
size
structur
natur
nucleotid
includ
abil
bind
within
activ
site
polymeras
abil
termin
polymeras
reaction
due
either
presenc
block
group
b
presenc
chemic
modif
group
nearbi
posit
sugar
ring
base
criteria
previous
test
activ
triphosph
form
sofosbuvir
alovudin
azt
rdrp
sarscov
three
triphosph
meutp
demonstr
abil
incorpor
two
coronaviru
rdrp
block
incorpor
also
demonstr
abil
activ
triphosph
form
tenofovir
tenofovir
diphosph
tfvdp
inhibit
rdrp
tenofovir
prodrug
often
use
combin
drug
emtricitabin
antivir
medic
report
activ
triphosph
form
tenofovir
emtricitabin
inhibitor
rdrp
catalyz
reaction
sidebysid
experi
tenofovir
diphosph
tfvdp
emtricitabin
triphosph
ectp
fig
c
g
activ
triphosph
form
two
viral
revers
transcriptas
inhibitor
hiv
hepat
b
viru
hbv
gilead
truvada
descovi
two
fdaapprov
medic
use
preexposur
prophylaxi
prep
prevent
hiv
infect
prep
prevent
method
individu
hiv
neg
highrisk
contract
viru
take
combin
drug
daili
reduc
chanc
becom
infect
hiv
truvada
descovi
consist
prodrug
emtricitabin
ftc
either
two
prodrug
form
tenofovir
tenofovir
disoproxil
fumar
tdf
truvada
tenofovir
alafenamid
taf
descovi
overal
combin
drug
well
toler
small
signific
reduct
number
patient
side
effect
latter
drug
often
includ
cocktail
patient
hivaid
critic
ensur
administ
drug
prep
hiv
neg
resist
mutat
observ
small
percentag
individu
use
ftc
plu
tdf
therefor
import
screen
seroconvers
possibl
drug
resist
tenofovir
alafenamid
taf
fig
prodrug
form
tfvdp
activ
seri
hydrolas
deprotect
monophosph
form
tenofovir
tfv
fig
two
consecut
kinas
reaction
tfvdp
fig
taf
show
potent
activ
hiv
hbv
limit
inhibit
host
nuclear
mitochondri
polymeras
tfvdp
acycl
nucleotid
notabl
group
upon
incorpor
hiv
hbv
polymeras
catalyz
reaction
nucleic
acid
elong
termin
viral
replic
stop
addit
resist
mutat
rare
occur
individu
treat
regimen
includ
taf
tdf
anoth
prodrug
tfvdp
differ
protect
group
use
mask
phosphat
comparison
taf
given
tenofovir
diphosph
tfvdp
common
activ
triphosph
form
taf
tdf
much
smaller
natur
nucleosid
triphosph
expect
easili
fit
within
activ
site
rdrp
acycl
nucleotid
tfvdp
lack
normal
sugar
ring
configur
thu
reason
unlik
recogn
involv
proofread
process
therebi
decreas
likelihood
develop
resist
inhibit
drug
base
analys
previous
demonstr
abil
tfvdp
inhibit
rdrp
inhibitori
effect
further
confirm
current
studi
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
emtricitabin
ftc
analog
contain
oxathiolan
ring
unnatur
blstereochem
configur
fig
prodrug
convert
cellular
enzym
first
monophosph
fig
activ
triphosph
form
ectp
fig
altern
prodrug
also
synthes
fig
absenc
oh
group
posit
ensur
nucleotid
analogu
incorpor
primer
polymeras
reaction
incorpor
nucleotid
polymeras
occur
like
taf
ftc
effect
retroviru
hiv
also
shown
inhibit
hbv
clinic
studi
due
structur
similar
molecul
previous
test
ftc
key
compon
descovi
truvada
ectp
activ
form
ftc
includ
rdrp
inhibitori
studi
test
abil
activ
triphosph
form
tenofovir
emtricitabin
incorpor
rdrp
rdrp
refer
two
protein
cofactor
whose
homolog
shown
requir
process
polymeras
activ
sarscov
clone
purifi
previous
describ
perform
polymeras
extens
assay
utp
tfvdp
utp
atp
ectp
follow
addit
preanneal
rna
templat
primer
preassembl
mixtur
rdrp
two
cofactor
protein
primer
extens
product
reaction
analyz
malditofm
rna
templat
primer
correspond
end
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
genom
use
polymeras
assay
sequenc
indic
top
fig
case
tenofovir
diphosph
tfvdp
contain
adenin
base
two
row
follow
u
next
avail
posit
templat
rna
polymeras
extens
downstream
prime
site
ad
utp
tfvdp
extens
reaction
base
result
previous
obtain
tfvdp
reduc
ratio
utp
tfvdp
current
experi
tfvdp
act
perman
termin
rdrp
reaction
would
ideal
observ
peak
spectrum
third
primer
extens
posit
caus
incorpor
two
us
one
tfvdp
case
emtricitabin
triphosph
ectp
c
analogu
need
extend
primer
first
avail
g
templat
sequenc
sinc
next
avail
posit
templat
consist
two
four
us
anoth
g
includ
utp
atp
ectp
extens
reaction
thu
ectp
serv
perman
inhibitor
rdrp
reaction
would
ideal
observ
peak
spectrum
eighth
primer
extens
posit
caus
incorpor
two
us
four
anoth
u
one
ectp
result
malditof
ms
analysi
primer
extens
product
shown
fig
observ
peak
gener
fit
predict
howev
addit
peak
product
assign
intermedi
stage
extens
reaction
also
observ
case
tfvdp
fig
peak
expect
molecular
weight
repres
incorpor
two
us
one
tfvdp
obtain
da
observ
da
expect
anticip
partial
extens
product
also
observ
singl
u
da
observ
da
expect
two
us
da
observ
da
expect
importantli
tfvdp
incorpor
extens
confirm
perman
termin
result
similar
previou
primer
extens
reaction
utp
tfvdp
howev
previous
observ
signific
amount
misincorpor
product
us
due
higher
concentr
utp
current
condit
misincorpor
insignific
fig
case
ectp
fig
expect
peak
indic
extens
three
us
four
one
ectp
observ
da
observ
da
expect
shorter
extens
product
also
occur
extens
one
u
da
observ
da
expect
longer
primer
extens
product
contain
sequenc
exclud
incorpor
ectp
da
observ
da
expect
extra
peak
right
da
could
explain
misincorpor
event
longer
primer
extens
product
contain
sequenc
da
expect
u
italic
incorpor
instead
c
follow
incorpor
occurr
misincorpor
indic
rdrp
low
fidel
properti
similar
rna
virus
summari
result
demonstr
nucleotid
analogu
tfvdp
ectp
perman
termin
rdrp
catalyz
reaction
prodrug
version
taf
tdf
emtricitabin
readili
synthes
use
protid
prodrug
approach
use
lead
compound
therapeut
develop
importantli
sinc
molecul
contain
fdaapprov
combin
drug
truvada
discovi
result
provid
molecular
basi
evalu
viru
inhibit
anim
model
test
efficaci
develop
potenti
medic
current
futur
studi
may
also
provid
potenti
option
prevent
infect
manner
similar
prep
hiv
prevent
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
fig
incorpor
tfvdp
ectp
rdrp
termin
polymeras
reaction
sequenc
primer
templat
use
extens
reaction
end
genom
shown
top
figur
polymeras
extens
reaction
perform
incub
utp
tfvdp
b
utp
atp
ectp
preassembl
polymeras
indic
rna
templat
primer
appropri
reaction
buffer
follow
detect
reaction
product
malditof
ms
detail
procedur
describ
method
section
accuraci
mz
determin
da
extens
reaction
rnadepend
rna
polymeras
oligonucleotid
purchas
integr
dna
technolog
primer
templat
sequenc
shown
fig
anneal
heat
min
cool
room
temperatur
reaction
buffer
rna
polymeras
mixtur
consist
cofactor
ratio
incub
min
room
temperatur
reaction
buffer
anneal
templat
primer
solut
contain
templat
primer
reaction
buffer
ad
rna
polymeras
mixtur
incub
addit
min
room
temperatur
final
solut
contain
either
mm
tfvdp
utp
mm
ectp
toronto
research
chemic
utp
atp
b
reaction
buffer
ad
incub
carri
hr
final
concentr
reagent
extens
reaction
nm
rna
primer
nm
rna
templat
either
tfvdp
utp
